Onesource Specialty Pharma is currently trading at Rs. 1564.00, up by 16.15 points or 1.04% from its previous closing of Rs. 1547.85 on the BSE.

The scrip opened at Rs. 1570.20 and has touched a high and low of Rs. 1574.00 and Rs. 1526.95 respectively. So far 515473 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2249.65 on 18-Jun-2025 and a 52 week low of Rs. 1075.00 on 30-Jan-2026.

Last one week high and low of the scrip stood at Rs. 1578.85 and Rs. 1480.00 respectively. The current market cap of the company is Rs. 17876.23 crore.

The promoters holding in the company stood at 30.48%, while Institutions and Non-Institutions held 38.11% and 31.41% respectively.

OneSource Specialty Pharma’s partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval for an Abbreviated New Drug Application (ANDA) for a generic version of Ozempic (Semaglutide Injection). The company is the contract development and manufacturing organization (CDMO) partner for this product.

This step highlights a closely integrated development-to-submission model: Orbicular led the product development and technical program for this complex peptide, while the company supported the program as the CDMO partner, providing end-to-end manufacturing capabilities for the U.S. market filing. The collaboration is designed to ensure reliable commercial supply from the company’s US-FDA approved flagship site in Bangalore.

OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.